Join to View Full Profile
675 N Saint Clair St# GalterChicago, IL 60611
Phone+1 312-695-0990
Fax+1 312-695-6189
Dr. Gordon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Leo Gordon is a hematologist based in Chicago, IL, with a subspecialty in hematologic oncology. He completed his medical education at the University of Cincinnati College of Medicine and pursued further training through an internship, residency, and fellowship at the University of Chicago, and an additional fellowship at the University of Minnesota. He has been an Assistant Professor of Medicine at Northwestern Medicine since 1979 and has expertise in non-Hodgkin lymphoma, hematologic oncology, stem cell, and bone marrow transplantation, and chronic lymphoid leukemia. His published research includes articles on kinase inhibitor delivery and treatment strategies for lymphoma. He has participated in several clinical trials related to lymphomas. His honors include a Fellow of the American College of Physicians and being recognized as a Super Doctor.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1979
University of MinnesotaFellowship, Hematology and Medical Oncology, 1978- University of ChicagoResidency, Internal Medicine, 1973 - 1976
- University of ChicagoInternship, Internal Medicine, 1973 - 1974
University of Cincinnati College of MedicineClass of 1973
Certifications & Licensure
IL State Medical License 1974 - 2026
MN State Medical License 1976 - 1978
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Northwestern Meaningful Use Data Warehouse Application for Eligible Providers, Northwestern University, 2011, 2013-2017
- CMS Meaningful Use Stage 1 Certification Northwestern Meaningful Use Data Warehouse Application for Eligible Providers, Northwestern University, 2011, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2017
Clinical Trials
- Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL Start of enrollment: 2003 Oct 28
- A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma Start of enrollment: 2006 Apr 07
- Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma Start of enrollment: 2007 Feb 06
Publications & Presentations
PubMed
- Recurrent Myocarditis After COVID Vaccination in a Patient With FLNC Mutation Undergoing Treatment for Lymphoma.Supreet Singh, Lucy C Campbell, Ike S Okwuosa, Lisa D Wilsbacher, Paul C Cremer
JACC. Case Reports. 2026-02-18 - 1 citationsOutcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.John S Wang, Brandon L Ellsworth, Megan Melody, Narendranath Epperla, Deborah Stephens
Blood Advances. 2026-02-10 - Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.Ranjana H Advani, Christopher R Kelsey, Philippe Armand, Celeste M Bello, Cecil M Benitez
Journal of the National Comprehensive Cancer Network. 2026-02-01
Abstracts/Posters
- Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Mul...Leo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma ModelLeo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...Leo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Inhibition of Pro-Survival Pathways in DLBCL Cells By Functional Lipoprotein-like Nanoparticles2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
VIDEO: Better Understanding of Minimal Residual Disease May Improve DLBCL CareOctober 24th, 2025- HMN 2025: How an Artificial Lipoprotein Targets Tumor Metabolism to Set off Cancer Cell DyingJune 6th, 2025
- Targeting Tumor Metabolism to Trigger Cancer Cell DeathJune 4th, 2025
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
